Education
About Us
Working with TipRanks
Follow Us
Kiniksa Pharmaceuticals (KNSA)
NASDAQ:KNSA
KNSA Stock Chart & Stats
$43.92
$0.18(0.88%)
At close: 4:00 PM EST
$43.92
$0.18(0.88%)
Day’s Range― - ―
52-Week Range$18.12 - $45.00
Previous CloseN/A
Volume84.12K
Average Volume (3M)554.98K
Market Cap
$3.33B
Enterprise Value$3.05B
Total Cash (Recent Filing)$352.10M
Total Debt (Recent Filing)$9.72M
Price to Earnings (P/E)97.9
Beta0.58
Next Earnings
Mar 03, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.23
Shares Outstanding45,161,020
10 Day Avg. Volume659,960
30 Day Avg. Volume554,980
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.22
Price to Sales (P/S)3.34
P/FCF Ratio55.59
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue5.11
Enterprise Value/Gross Profit9.68
Enterprise Value/Ebitda67.72
Forecast
1Y Price Target
$53.60Price Target Upside22.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)1.52
Revenue Forecast (FY)$906.81M
Bulls Say, Bears Say
Bulls Say
KPL-387 Product PotentialAnalyst highlights KPL-387 as a next-generation asset that could be dosed less frequently than Arcalyst, which may improve patient compliance and extend the product franchise if development succeeds.
Market PenetrationAnalyst notes rising patient enrollments, a broader prescriber base, and increasing repeat prescriptions, indicating deeper and expanding adoption of Arcalyst.
Sales GuidanceAnalyst reports Arcalyst's strong sales performance led management to raise full-year sales guidance, signaling upward revenue momentum for the company.
Bears Say
Clinical And Regulatory RiskKPL-387 remains in clinical development, exposing the company to clinical trial setbacks and regulatory hurdles before the asset can materially impact revenue or profitability.
Conditional Financial UpsideFuture revenue and profit gains tied to KPL-387 are contingent on successful clinical results and approvals, making the anticipated upside uncertain until those milestones are met.
Timing Risk For Pipeline-driven GrowthDelays or complications in KPL-387's development or approval process could postpone expected earnings benefits and limit near-term valuation upside.
Kiniksa Pharmaceuticals News
KNSA FAQ
What was Kiniksa Pharmaceuticals’s price range in the past 12 months?
Kiniksa Pharmaceuticals lowest stock price was $18.12 and its highest was $45.00 in the past 12 months.
What is Kiniksa Pharmaceuticals’s market cap?
Kiniksa Pharmaceuticals’s market cap is $3.33B.
When is Kiniksa Pharmaceuticals’s upcoming earnings report date?
Kiniksa Pharmaceuticals’s upcoming earnings report date is Mar 03, 2026 which is in 28 days.
How were Kiniksa Pharmaceuticals’s earnings last quarter?
Kiniksa Pharmaceuticals released its earnings results on Oct 28, 2025. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.324 by -$0.094.
Is Kiniksa Pharmaceuticals overvalued?
According to Wall Street analysts Kiniksa Pharmaceuticals’s price is currently Undervalued.
Does Kiniksa Pharmaceuticals pay dividends?
Kiniksa Pharmaceuticals does not currently pay dividends.
What is Kiniksa Pharmaceuticals’s EPS estimate?
Kiniksa Pharmaceuticals’s EPS estimate is 0.32.
How many shares outstanding does Kiniksa Pharmaceuticals have?
Kiniksa Pharmaceuticals has 45,161,020 shares outstanding.
What happened to Kiniksa Pharmaceuticals’s price movement after its last earnings report?
Kiniksa Pharmaceuticals reported an EPS of $0.23 in its last earnings report, missing expectations of $0.324. Following the earnings report the stock price went down -2.882%.
Which hedge fund is a major shareholder of Kiniksa Pharmaceuticals?
Currently, no hedge funds are holding shares in KNSA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kiniksa Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.60 (22.04% Upside)
$53.60 (22.04% Upside)
Blogger Sentiment
Bullish
KNSA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 193.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
120.92%
12-Months-Change
Fundamentals
Return on Equity
7.39%
Trailing 12-Months
Asset Growth
28.28%
Trailing 12-Months
Company Description
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
KNSA Company Deck
KNSA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive outlook for Kiniksa Pharmaceuticals with significant revenue growth, increased sales guidance, and a robust financial position. The company highlights the increased adoption of ARCALYST and its FDA Orphan Drug Designation for KPL-387. However, challenges remain with limited market penetration and increased operating expenses.View all KNSA earnings summariesKNSA Stock 12 Month Forecast
Average Price Target
$53.60
▲(22.04% Upside)
Technical Analysis
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
CG Oncology, Inc.
―
Ownership Overview
7.26% Insiders
14.37% Mutual Funds
0.26% Other Institutional Investors
67.19% Public Companies and
Individual Investors